Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus analgesics with concurrent chemoradiotherapy for pain control in locally advanced head and neck squamous cell carcinoma
ChiCTR2100044100Phase 4Recruiting
- Sponsor
- Baotou Cancer Hospital
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of nimotuzumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Baotou Cancer Hospital. Primary endpoint: NRS score. Started May 2021; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100044100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044100.